A fungicidal monoclonal antibody protects against murine invasive candidiasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 51 citations in OpenAlex.

1. A Synthetic β-Mannan Epitope Enables Immunization and Detection of Candida auris.Angewandte Chemie (International ed. in English) · 2026
   Article
2. Antifungal Innate Immunity.Advances in experimental medicine and biology · 2025
   Review
3. Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024
   Review
4. Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024
   Review
5. Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020
   Review
6. Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020
   Review
7. The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?Frontiers in pharmacology · 2019
   Review
8. Human monoclonal antibody-based therapy in the treatment of invasive candidiasis.Clinical & developmental immunology · 2013
   Review
9. Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans.Antimicrobial agents and chemotherapy · 2011
   Article
10. Candida albicans Als3, a multifunctional adhesin and invasin.Eukaryotic cell · 2011
    Review
11. Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.Infection and immunity · 2010
    Article
12. Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity.PloS one · 2009
    Article
13. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence.PloS one · 2009
    Article
14. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis.Proceedings of the National Academy of Sciences of the United States of America · 2008
    Article
15. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.PloS one · 2008
    Article
16. Glycoconjugates and polysaccharides of fungal cell wall and activation of immune system.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2008
    Article
17. Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.Infection and immunity · 2007
    Review
18. Fungicidal monoclonal antibody C7 binds to Candida albicans Als3.Infection and immunity · 2007
    Article
19. Advances in combating fungal diseases: vaccines on the threshold.Nature reviews. Microbiology · 2007
    Review
20. Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy.Mycopathologia
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 3 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as